Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers

OBJECTIVE: This study assessed relative bioavailability of a new subcutaneous formulation, test (T) (dalteparin sodium 95000 IU/3.8 mL) with the branded product (R) in healthy subjects to meet the regulatory requirements of bioequivalence in the US. METHODS: This was an open label, randomized, singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadiko, C., Tippabhotla, S. K., Thota, S., Nakkawar, M., Cheerla, R., Betha, M.R., Vobalaboina, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Maney Publishing 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937650/
https://www.ncbi.nlm.nih.gov/pubmed/27536434
http://dx.doi.org/10.3109/21556660.2013.781504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937650/
https://www.ncbi.nlm.nih.gov/pubmed/27536434
http://dx.doi.org/10.3109/21556660.2013.781504

Ejemplares similares